Cancer
MK-2870-032
Breast Cancer
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for Triple-Negative
Contact Research Team:
[email protected]
Site principal investigator:
Kelly Gast, MD
Learn more about this study:
NCT06966700